1Oberg K. Pancreatic endocrine tumors[J]. Semin Oncol, 2010, 37(6): 594-618.
2Halfdanarson TR, Rubin J, Farnell MB, et al. Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors[J]. Endocr Relat Cancer, 2008, 15(2): 409-427.
3Key C. Cancer of the pancreas[M]//Ries LAG, Young JL, Keel GE, et al. SEER Survival Monograph Bethesda. MD: NIH Publishers, 2007: 59-65.
4Irvin MM, Kjell O, Daniel CC, et al. Gastroenteropancreatic neuroendoerine tumors[J]. Lancet Oneol, 2008, 9(12): 61.
5Ehehalt F, Saeger H, Schmidt C, et al. Neuroendocrine tumors of the pancreas[J]. Oncologist, 2009, 12: 456-467.
6Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35 825 cases in the United States[J]. J Clin Oncol, 2008, 26(18): 3063-3072.
7Halfdanarson TR, Rabe KG, Rubin J, et al. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival[J]. Ann Oncol, 2008, 19(5A): 1727-1733.
8Sarmiento JM, Famell MB, Que FG, et al. Pancreaticodu-odenectomy for islet cell tumors of head of the pancreas:Long-term survival analysis [J].World J Surg, 2002, 26(10): 1267-71.
9Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil,doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas[J]. J Clin Oncol,2004, 22(23): 4762.
10John DH, David R, Litchy S, et al. Phase II trial of paclitaxel,carboplatin,and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a minnie pearl cancer research network study [J]. J Clin Oncol,2006, 24(22): 3548.
